Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicentre, International Study With a Parallel, Randomised, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET)

Next Previous
Trial Profile

A Phase III, Multicentre, International Study With a Parallel, Randomised, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selumetinib (Primary)
  • Indications Neurofibromatosis 1; Plexiform neurofibroma
  • Focus Registrational; Therapeutic Use
  • Acronyms KOMET
  • Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

  • 10 Apr 2026 Results presented in the AstraZeneca Rare Disease Media Release
  • 10 Apr 2026 According to AstraZeneca Rare Disease media release, data from the trial will be presented at the American Academy of Neurology (AAN) Annual Meeting in Chicago, Illinois, 18 to 22 April 2026.
  • 09 Mar 2026 According to an AstraZeneca media release, based on results from KOMET, Koselugo (selumetinib), has been approved in Canada for the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top